대한의생명과학회지 (Biomedical Science Letters)

  • 제25권2호
  • /
  • Pages.159-169
  • /
  • 2019
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

Dual Drug-Loaded Liposomes for Synergistic Efficacy in MCF-7 Breast Cancer Cells and Cancer Stem Cells

  • Park, Hee-Bin (Department of Biomedical Laboratory Science, Konyang University) ;
  • Kim, Yun-Ji (Department of Biomedical Laboratory Science, Konyang University) ;
  • Lee, Seong-Min (Department of Biomedical Laboratory Science, Konyang University) ;
  • Park, James S. (NYU Langone Health) ;
  • Kim, Keun-Sik (Department of Biomedical Laboratory Science, Konyang University)
  • 투고 : 2019.04.19
  • 심사 : 2019.05.22
  • 발행 : 2019.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Breast cancer stem cells (BCSCs) in breast cancer cells have self-renewal ability and differentiation potential. They are also resistant to drugs after chemotherapy. To overcome this resistance, we designed negatively charged 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG)-based liposomes for drug delivery. These liposomes have enhanced the therapeutic effects of a range of antitumor therapies by increasing the cellular uptake and improving drug delivery to targets sites. In this study, we investigated whether DMPG-POPC liposomes, including the neutral lipid 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholin (POPC), can specifically bind to MCF-7 breast cancer cells and increase cellular uptake compared with that by CHOL-POPC liposomes. We also estimated the cytotoxicity of DMPG-POPC liposomes encapsulated with both metformin (Met) and sodium salicylate (Sod) against breast cancer cells and BCSCs compared with that of the free drugs. Our results demonstrated that these dual drug-encapsulated liposomes significantly enhanced the cytotoxic and anti-colony formation abilities compared with individual drug-encapsulated liposomes or free drugs in BCSCs. Overall, our results suggest that DMPG-POPC liposomes containing two drugs (Met + Sod) show promise for synergistic anti-cancer therapy of breast cancer by increasing drug delivery efficiency into breast cancer cells and BCSCs.

키워드

참고문헌

  1. Alhariri M, Majrashi MA, Bahkali AH, Almajed FS, Azghani AO, Khiyami MA, Alyamani EJ, Aljohani SM, Halwani MA. Efficacy of neutral and negatively charged liposome-loaded gentamicin on planktonic bacteria and biofilm communities. Int J Nanomedicine. 2017. 12: 6949-6961. https://doi.org/10.2147/IJN.S141709
  2. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009. 8: 909-915. https://doi.org/10.4161/cc.8.6.7933
  3. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013. 65: 36-48. https://doi.org/10.1016/j.addr.2012.09.037
  4. Amann R, Peskar BA. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol. 2002. 447: 1-9. https://doi.org/10.1016/S0014-2999(02)01828-9
  5. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, Sarkar FH. Metformin inhibits cell proliferation, migration and invasion by attenuating csc function mediated by deregulating mirnas in pancreatic cancer cells. Cancer Prev Res. 2012. 5: 355-364. https://doi.org/10.1158/1940-6207.CAPR-11-0299
  6. Bellosillo B, Pique M, Barragan M, Castano E, Villamor N, Colomer D, Montserrat E, Pons G, Gil J. Aspirin and salicylate induce apoptosis and activation of caspases in b-cell chronic lymphocytic leukemia cells. Blood. 1998. 92: 1406-1414. https://doi.org/10.1182/blood.V92.4.1406
  7. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006. 29: 254-258. https://doi.org/10.2337/diacare.29.02.06.dc05-1558
  8. De Jong WH, Borm PJA. Drug delivery and nanoparticles: Applications and hazards. International Journal of Nanomedicine. 2008. 3: 133-149. https://doi.org/10.2147/IJN.S596
  9. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005. 5: 275-284. https://doi.org/10.1038/nrc1590
  10. Dikshit P, Chatterjee M, Goswami A, Mishra A, Jana NR. Aspirin induces apoptosis through the inhibition of proteasome function. J Biol Chem. 2006. 281: 29228-29235. https://doi.org/10.1074/jbc.M602629200
  11. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007. 67: 10804-10812. https://doi.org/10.1158/0008-5472.CAN-07-2310
  12. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. Bmj. 2005. 330: 1304-1305. https://doi.org/10.1136/bmj.38415.708634.F7
  13. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet. 2007. 369: 1603-1613. https://doi.org/10.1016/S0140-6736(07)60747-8
  14. Gangemi R, Paleari L, Orengo AM, Cesario A, Chessa L, Ferrini S, Russo P. Cancer stem cells: A new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem. 2009. 16: 1688-1703. https://doi.org/10.2174/092986709788186147
  15. Han JS, Crowe DL. Tumor initiating cancer stem cells from human breast cancer cell lines. Int J Oncol. 2009. 34: 1449-1453.
  16. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A. 2013. 110: 972-977. https://doi.org/10.1073/pnas.1221055110
  17. Jeong K, Kang CS, Kim Y, Lee YD, Kwon IC, Kim S. Development of highly efficient nanocarrier-mediated delivery approaches for cancer therapy. Cancer Lett. 2016. 374: 31-43. https://doi.org/10.1016/j.canlet.2016.01.050
  18. Ji P, Zhang Y, Wang SJ, Ge HL, Zhao GP, Xu YC, Wang Y. Cd44hicd24lo mammosphere-forming cells from primary breast cancer display resistance to multiple chemotherapeutic drugs. Oncol Rep. 2016. 35: 3293-3302. https://doi.org/10.3892/or.2016.4739
  19. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009. 27: 3297-3302. https://doi.org/10.1200/JCO.2009.19.6410
  20. Lee EJ. Cancer chemoprevention effects of geldanamycin and 17-aag in human oral squamous cell carcinoma. Korean Journal of Clinical Laboratory Science. 2018. 50: 462-469. https://doi.org/10.15324/kjcls.2018.50.4.462
  21. Kai M, Kanaya N, Wu SV, Mendez C, Nguyen D, Luu T, Chen S. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of lbh589 and salinomycin. Breast Cancer Res Treat. 2015. 151: 281-294. https://doi.org/10.1007/s10549-015-3376-5
  22. Kim J-E, Kang B-I, Bae S-M, Han S, Jun A, Han J, Cho M-A, Choi Y-L, Lee J-H, Moon Y-H. An analytical validation of the geneswell tm bct multigene prognostic test in patients with early breast cancer. Korean Journal of Clinical Laboratory Science. 2017a. 49: 79-87. https://doi.org/10.15324/kjcls.2017.49.2.79
  23. Kim Y-J, Park H-B, Kim P-H, Park JS, Kim K-S. Enhanced anticancer efficacy in mcf-7 breast cancer cells by combined drugs of metformin and sodium salicylate. Biomedical Science Letters. 2017b. 23: 290-294. https://doi.org/10.15616/BSL.2017.23.3.290
  24. Klampfer L, Cammenga J, Wisniewski H-G, Nimer S. Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines. Blood. 1999. 93: 2386-2394. https://doi.org/10.1182/blood.V93.7.2386
  25. Law BK, Waltner-Law ME, Entingh AJ, Chytil A, Aakre ME, Norgaard P, Moses HL. Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin d1, cyclin a, and proliferating cell nuclear antigen. J Biol Chem. 2000. 275: 38261-38267. https://doi.org/10.1074/jbc.M005545200
  26. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008. 100: 672-679. https://doi.org/10.1093/jnci/djn123
  27. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care. 2009. 32: 1620-1625. https://doi.org/10.2337/dc08-2175
  28. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009. 8: 2031-2040. https://doi.org/10.4161/cc.8.13.8814
  29. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005. 205: 275-292. https://doi.org/10.1002/path.1706
  30. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest. 2005. 115: 44-55. https://doi.org/10.1172/JCI22320
  31. Mukherjee S, Mazumdar M, Chakraborty S, Manna A, Saha S, Khan P, Bhattacharjee P, Guha D, Adhikary A, Mukhjerjee S, Das T. Curcumin inhibits breast cancer stem cell migration by amplifying the e-cadherin/beta-catenin negative feedback loop. Stem Cell Res Ther. 2014. 5:116. https://doi.org/10.1186/scrt506
  32. Nag O, Yadav V, Hedrick A, Awasthi V. Post-modification of preformed liposomes with novel non-phospholipid poly(ethylene glycol)-conjugated hexadecylcarbamoylmethyl hexadecanoic acid for enhanced circulation persistence in vivo. International Journal of Pharmaceutics. 2013. 446: 119-129. https://doi.org/10.1016/j.ijpharm.2013.02.026
  33. Song X, Ren Y, Zhang J, Wang G, Han X, Zheng W, Zhen L. Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized dotap/dope liposomes. Oncol Rep. 2015. 34: 1953-1960. https://doi.org/10.3892/or.2015.4136
  34. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat Rev Cancer. 2006. 6: 130-140. https://doi.org/10.1038/nrc1801
  35. Vinogradov S, Wei X. Cancer stem cells and drug resistance: The potential of nanomedicine. Nanomedicine. 2012. 7: 597-615. https://doi.org/10.2217/nnm.12.22
  36. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of amp-activated protein kinase. Cancer Prev Res. 2008. 1: 369-375. https://doi.org/10.1158/1940-6207.CAPR-08-0081
  37. Zhang Z, Ni C, Chen W, Wu P, Wang Z, Yin J, Huang J, Qiu F. Expression of cxcr4 and breast cancer prognosis: A systematic review and meta-analysis. BMC Cancer. 2014. 14: 1471-2407.
  38. Zou Y, Priebe W, Perez-Soler R. Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: Effect of surfactant on liposome formation, stability and size. Cancer Chemother Pharmacol. 1996. 39: 103-108. https://doi.org/10.1007/s002800050544